Eiger Biopharmaceuticals (EIGR) Reaches New 1-Year High at $14.56

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) hit a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $14.56 and last traded at $14.05, with a volume of 97000 shares traded. The stock had previously closed at $13.95.

Several equities research analysts have issued reports on EIGR shares. Oppenheimer set a $34.00 price target on Eiger Biopharmaceuticals and gave the stock a “buy” rating in a report on Thursday, December 7th. Zacks Investment Research downgraded Eiger Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Wedbush reaffirmed a “buy” rating on shares of Eiger Biopharmaceuticals in a research report on Wednesday, October 25th. Ladenburg Thalmann Financial Services started coverage on Eiger Biopharmaceuticals in a research report on Wednesday. They set a “buy” rating and a $32.00 price objective for the company. Finally, ValuEngine raised Eiger Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $30.63.

The company has a quick ratio of 5.78, a current ratio of 5.78 and a debt-to-equity ratio of 1.19. The firm has a market cap of $154.59, a PE ratio of -2.74 and a beta of 2.54.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.28) by $0.18. equities analysts predict that Eiger Biopharmaceuticals Inc will post -4.59 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wedbush Securities Inc. acquired a new position in Eiger Biopharmaceuticals during the third quarter valued at approximately $114,000. Susquehanna International Group LLP acquired a new position in Eiger Biopharmaceuticals during the second quarter valued at approximately $114,000. Bank of New York Mellon Corp boosted its position in Eiger Biopharmaceuticals by 6.4% during the second quarter. Bank of New York Mellon Corp now owns 14,567 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 871 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Eiger Biopharmaceuticals by 295.8% during the third quarter. JPMorgan Chase & Co. now owns 11,705 shares of the biotechnology company’s stock valued at $126,000 after purchasing an additional 8,748 shares during the last quarter. Finally, OxFORD Asset Management LLP acquired a new position in Eiger Biopharmaceuticals during the third quarter valued at approximately $147,000. 47.06% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3126338/eiger-biopharmaceuticals-eigr-reaches-new-1-year-high-at-14-56.html.

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2018 Ticker Report. Google+.